Viskase Holdings, Inc.

VISK ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Operating Activities
Net Income $5.4M $-1.1M $21.6M $28.8M $18.2M $-2.8M $-20.8M $177.2M
Depreciation & Amortization — — — $0 $232.0K $4.3M $5.3M $5.8M
Depreciation — — — — $200.0K $4.3M $5.3M $5.8M
Amortization — — — — — — — —
Stock-Based Compensation — — — $0 $-205.0K $2.1M $3.1M $6.9M
Net Cash from Operating Activities $6.5M $2.6M $14.7M $32.3M $14.0M $8.5M $-12.7M $22.6M
Investing Activities
Capital Expenditures — — — — $0 $23.0K $630.0K $2.0M
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities — — — — — $97.6M $-159.2M $344.0M
Financing Activities
Dividends Paid $6.6M $6.6M $37.6M $4.4M $89.8M $87.3M $0 —
Stock Repurchases — — — — $0 $31.7M $120.8M $48.2M
Net Cash from Financing Activities $-6.6M $-6.6M — — — $-133.0M $-121.2M $-19.5M
Net Change in Cash $-161.0K $-4.0M $-22.9M $28.0M $-70.8M $-27.0M $-293.2M $347.1M
Free Cash Flow — — — — $14.0M $8.4M $-13.4M $20.6M
← Newer Page 2 of 3 Older →